Alicja Correll, DO
Family Medicine · West Sacramento, CANPI 1215426283
Payments from drug & device makers
Across 356 payments — averaging $20.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$842
- Bayer$824
- Pfizer$645
- AbbVie$535
- Boehringer Ingelheim$464
- plus $3K from 30 others
What the payments were for
- Food & beverage$7,402100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 51 | $1,132 |
| Lilly USA, LLC | 41 | $842 |
| Bayer | 33 | $824 |
| Pfizer | 42 | $645 |
| AbbVie | 22 | $535 |
| Boehringer Ingelheim | 21 | $464 |
| Johnson & Johnson | 14 | $315 |
| AstraZeneca | 21 | $301 |
| Abbott | 12 | $297 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $258 |
| Merck | 10 | $216 |
| GSK | 8 | $163 |
| Dexcom, Inc. | 5 | $150 |
| Exact Sciences | 6 | $142 |
| Amgen | 9 | $137 |
| Sanofi-aventis U.S. LLC | 6 | $126 |
| Medtronic | 2 | $98 |
| Phadia US Inc. | 5 | $94 |
| Cranial Technologies, Inc | 5 | $75 |
| Sanofi Pasteur Inc. | 3 | $75 |
| Biohaven Pharmaceuticals, Inc. | 3 | $65 |
| Intra-sana Laboratories | 3 | $59 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $51 |
| Vertex | 2 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $42 |
| Novartis | 2 | $40 |
| Alnylam Pharmaceuticals Inc. | 2 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $30 |
| Xeris Pharmaceuticals, Inc. | 2 | $30 |
| Aimmune Therapeutics, Inc. | 1 | $29 |
| Sanofi | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Novavax Inc | 1 | $15 |
| VBI Vaccine (delaware) Inc. | 1 | $11 |
| Mayne Pharma Commercial LLC | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$122
How this compares
$7,410 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 44 | $64,659 |
| OzempicSemaglutide | 43 | $63,755 |
| EliquisApixaban | 34 | $43,549 |
| RybelsusSemaglutide | 15 | $41,774 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $31,542 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $16,010 |
| JanuviaSitagliptin Phosphate | 14 | $14,977 |
| Spiriva RespimatTiotropium Bromide | 13 | $12,766 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 334 | $8,976 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $8,502 |
| XareltoRivaroxaban | 13 | $7,372 |
| Lacosamide | 16 | $5,932 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $5,826 |
| Doxepin Hcl | 15 | $5,147 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $3,941 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,132 | $105,52958 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $464 | $83,25269 claims |
| PfizerEliquis | $645 | $43,54934 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $163 | $35,48234 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $301 | $24,51130 claims |
| MerckJanuvia | $216 | $14,97714 claims |
| Johnson & JohnsonXarelto | $315 | $7,37213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in West Sacramento
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.